PSP Canada
Overview
PSP Canada (Progressive Supranuclear Palsy Canada) is a Canadian national organization dedicated to supporting patients, families, and caregivers affected by Progressive Supranuclear Palsy (PSP), a rare neurodegenerative tauopathy. Founded to address the significant unmet needs in PSP patient care and research, PSP Canada serves as a critical hub for disease awareness, patient advocacy, and funding of cutting-edge neuroscience research. The organization operates within the context of Canada's healthcare system and collaborates with researchers, clinicians, and patient communities across the country to advance understanding of this devastating neurological condition.
Progressive Supranuclear Palsy itself is a rapidly progressive, atypical parkinsonian disorder characterized by vertical supranuclear gaze palsy, postural instability, bradykinesia, and cognitive decline. With an estimated prevalence of 5-6 cases per 100,000 population, PSP represents one of the most common atypical parkinsonisms in North America, yet remains significantly underdiagnosed and underrecognized. PSP Canada works to bridge diagnostic gaps and ensure patients receive timely, accurate diagnoses and appropriate multidisciplinary care.
Function/Biology
...PSP Canada
Overview
PSP Canada (Progressive Supranuclear Palsy Canada) is a Canadian national organization dedicated to supporting patients, families, and caregivers affected by Progressive Supranuclear Palsy (PSP), a rare neurodegenerative tauopathy. Founded to address the significant unmet needs in PSP patient care and research, PSP Canada serves as a critical hub for disease awareness, patient advocacy, and funding of cutting-edge neuroscience research. The organization operates within the context of Canada's healthcare system and collaborates with researchers, clinicians, and patient communities across the country to advance understanding of this devastating neurological condition.
Progressive Supranuclear Palsy itself is a rapidly progressive, atypical parkinsonian disorder characterized by vertical supranuclear gaze palsy, postural instability, bradykinesia, and cognitive decline. With an estimated prevalence of 5-6 cases per 100,000 population, PSP represents one of the most common atypical parkinsonisms in North America, yet remains significantly underdiagnosed and underrecognized. PSP Canada works to bridge diagnostic gaps and ensure patients receive timely, accurate diagnoses and appropriate multidisciplinary care.
Function/Biology
PSP Canada functions as both a patient advocacy organization and a research catalyst, supporting multiple dimensions of disease management and investigation. The organization coordinates national awareness campaigns, maintains patient registries, facilitates support groups, and provides educational resources about PSP pathology and clinical management. PSP Canada also works to identify and connect affected individuals with specialized movement disorder clinicians capable of recognizing and diagnosing PSP, which frequently requires sophisticated neuroimaging and clinical expertise.
At the biological level, PSP is fundamentally a tau proteinopathy—a disease characterized by pathological accumulation of tau protein in the brain. Tau normally functions as a microtubule-associated protein essential for neuronal cytoskeletal stability and axonal transport. In PSP, hyperphosphorylated tau misfolds and aggregates into neurofibrillary tangles and tufted astrocytes, predominantly affecting the brainstem, midbrain, basal ganglia, and prefrontal cortex. This tau pathology disrupts cellular architecture, impairs neuronal transport, and triggers neuroinflammatory cascades.
Role in Neurodegeneration
PSP Canada addresses a condition that exemplifies multiple neurodegenerative mechanisms. PSP involves progressive neuronal death in anatomically distributed brain regions, with particular vulnerability of dopaminergic, cholinergic, and glutamatergic systems. The vertical supranuclear gaze palsy reflects midbrain oculomotor nucleus degeneration, while cognitive decline reflects prefrontal and superior temporal pathology. The organization supports research investigating how tau pathology initiates and propagates between neurons, potentially through mechanisms involving tau seeding and prion-like mechanisms.
Recent investigations supported through PSP Canada and international collaborators have revealed that PSP involves more than isolated tau pathology—it frequently includes concurrent TDP-43 proteinopathy and amyloid-beta pathology, particularly in older patients, suggesting overlap with Alzheimer's disease and frontotemporal dementia spectrum disorders.
Molecular Mechanisms
At the molecular level, PSP involves several interconnected pathological processes. Tau hyperphosphorylation occurs through dysregulation of kinases (including GSK-3β and CDK5) and phosphatases (particularly PP2A). The resulting tau aggregates sequester normal tau and other microtubule-binding proteins, compromising microtubule stability and disrupting axonal transport of essential organelles and proteins. This disruption of anterograde and retrograde transport impairs neuronal energy metabolism and synaptic function.
PSP pathology also engages the unfolded protein response and proteasomal/autophagic degradation systems, with impaired protein clearance contributing to progressive tau accumulation. Neuroinflammation involving microglial activation, astrogliosis, and pro-inflammatory cytokine production amplifies neuronal injury.
Clinical/Research Significance
PSP Canada plays a crucial role in facilitating clinical trials and observational studies investigating tau-targeting therapeutics, including tau aggregation inhibitors, immunotherapies targeting pathological tau, and neuroprotective approaches. The organization helps recruit patients for multicenter studies and maintains biobanks for tau pathology research. As disease-modifying therapies targeting tau emerge, PSP Canada ensures Canadian patients have equitable access to clinical investigations and future treatments.
PSP Canada collaborates with international organizations including the PSP Association (United Kingdom) and PSP Advocates (United States), neurodegenerative disease foundations, and Canadian academic movement disorder centers specializing in atypical parkinsonisms and tauopathies.
Pathway Diagram
The following diagram shows the key molecular relationships involving PSP Canada discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)